The Mosquirix malaria vaccine price cut, a roughly 40% reduction to €5.50 a dose agreed by UNICEF and Gavi, is also a story about India: production of the world’s first approved malaria vaccine is being transferred from GSK to Hyderabad-based Bharat Biotech. The agreement was reported on 22 October 2026, and the lower price depends on regulatory and manufacturing milestones, including WHO prequalification of a new facility.
Key takeaways: the Mosquirix malaria vaccine price cut and India’s role
- UNICEF and Gavi agreed to cut the price of Mosquirix by about 40% to €5.50 per dose, with savings of about US$50 million over 2027 to 2029.
- Bharat Biotech is taking over production in a technology transfer from GSK, with full takeover targeted for 2028.
- GSK is expected to keep supplying the vaccine’s adjuvant after the transfer.
- The price should apply by early 2027, once milestones, including WHO prequalification of a new facility, are met.
- The Mosquirix malaria vaccine price cut builds on a 2025 plan by GSK and Bharat Biotech to bring the price below US$5 by 2028.
Why Bharat Biotech’s role in the Mosquirix malaria vaccine price cut matters
Technology transfer means the original developer shares the know-how needed to make a product, and the receiving company sets up its own production. Here, GSK and the nonprofit PATH developed the vaccine, known scientifically as RTS,S/AS01, and Bharat Biotech will become the manufacturer. According to the report, GSK will continue to supply the adjuvant, the ingredient that strengthens the immune response, after Bharat takes over.
For India’s vaccine sector, the transfer places a domestic company at the centre of a global malaria programme. India is already a major vaccine producer, and the report notes that last year Gavi and UNICEF agreed a 25% price cut for a malaria vaccine made by the Serum Institute of India. That makes India the production base for both malaria vaccines in use, a point we draw from the report and not from either company.
What a technology transfer involves
A transfer of this kind is not a single event. In general terms, and without claiming these are the exact steps GSK and Bharat Biotech are following, it moves through stages that the report does not detail:
- Process know-how is documented and shared with the receiving manufacturer.
- The receiving site installs and qualifies equipment, then makes trial batches.
- Regulators and, for UN purchases, the WHO review the site and compare product quality with the original.
- Commercial supply begins, often with the originator still providing some inputs, as GSK will with the adjuvant.
Each stage can take longer than planned, which is why the reported conditions matter. The company’s own website, bharatbiotech.com, is where official updates would appear.
The price and savings in the Mosquirix malaria vaccine price cut
The report says the price falls by about 40% to €5.50 per dose, which our approximate conversion puts at roughly US$6. By our own arithmetic, that implies a prior price of about €9 per dose, though the report as we read it does not state the earlier figure. The expected saving is about US$50 million between 2027 and 2029, which depends on how many doses are ordered.
Last year GSK and Bharat Biotech said they planned to bring the price below US$5 per dose by 2028. The new price is above that target, so the Mosquirix malaria vaccine price cut should be read as an interim step towards a lower price, according to the report. We have not seen a new commitment on the sub-US$5 target.
Conditions before the Mosquirix malaria vaccine price cut applies
The report says the agreement is subject to regulatory and manufacturing milestones before UNICEF begins purchasing at the new price. One named condition is WHO prequalification of a new manufacturing facility. Prequalification is how the WHO verifies quality for vaccines that UN agencies purchase, and it normally involves reviewing the manufacturing site and the product data.
Timelines for such processes can move. If the new facility were delayed, the lower price could be delayed too. The report does not give a prequalification date, and we do not guess one.
General background: malaria vaccines and affordability
Malaria still causes a large number of child deaths in sub-Saharan Africa, according to the World Health Organization. Vaccines supplement bed nets and medicines rather than replace them. Because vaccines are given in multiple doses, a lower unit price lets a fixed budget cover more children, which is why price negotiations matter. See also our pharmaceutical coverage.
Our analysis: what the Mosquirix malaria vaccine price cut means for India’s manufacturers
In our assessment, the Mosquirix malaria vaccine price cut is a useful example of how Indian manufacturers can combine scale with technology transfer to reduce global health costs. It is not yet proof that the transfer will succeed. Moving a complex vaccine, with a specialised adjuvant supplied from outside India, requires validated processes and regulatory approval of the new site.
Readers should also note that the savings are modest in the global context, and that the agreement does not by itself fund more vaccinations. We offer this as analysis, not as a statement by the companies. We have no data from Bharat Biotech on capacity, investment or timelines.
What is not disclosed about the Mosquirix malaria vaccine price cut
- The prior price and the precise exchange rate.
- Bharat Biotech’s planned capacity and investment.
- The date of WHO prequalification for the new facility.
- Commercial terms between GSK, PATH and Bharat Biotech.
Risks and caveats
The agreement depends on milestones, and technology transfers can face delays. This article relies on a single wire report, and the dollar figure is our approximate conversion. Vaccine rollout also depends on funding and national programmes, which are outside this agreement. This is news reporting and not medical advice.
What to watch next after the Mosquirix malaria vaccine price cut
- WHO prequalification news for the new site, via the Gavi and WHO channels.
- Bharat Biotech’s production ramp-up towards 2028.
- Confirmation that the new price is in effect in early 2027.
- Any new price commitment below US$5 per dose.
FAQ
What is the Mosquirix malaria vaccine price cut?
It is an agreement by UNICEF and Gavi to buy Mosquirix at about 40% less, €5.50 per dose, from early 2027 if conditions are met.
Why is Bharat Biotech involved?
Production is being transferred from GSK to Bharat Biotech, with full takeover targeted for 2028.
Does this make the vaccine available in India?
The report concerns purchases by UNICEF and Gavi for supported countries. It does not describe use in India’s national programme.
How we reported this: we relied on a wire-service report and attributed every figure to it. Conversions and estimates are labelled as ours. Last updated 23 October 2026. This is news reporting and not advice.
